If an add-on controller is required, young people in this arm will be prescribed personalised medicine by results of the genotyping for the adrenergic beta2-receptor gene (ADRB2). Health professional's will be advised to prescribe inhaled salmeterol as 'add-on' controller if trial participants have the Gly/Gly variant on ADRB2, and montelukast if they have Arg/Arg or Arg/Gly variant on ADRB2.

If an add-on controller is required, young people will be prescribed medication as per the choice of the primary or secondary care physician, without knowledge of genotypic status.

Asthma

If participants require add-on medication and have the Gly/Gly variant on the ADRB2, salmeterol will be prescribed.

Personalised medicine (Salmeterol)

If participants require add-on medication and have the Arg/Arg or Arg/Gly variant on the ADRB2, montelukast will be prescribed.

Personalised medicine (Montelukast)

If participants require add-on medication in the arm, they will be prescribed either salmeterol or montelukast according to health professional's choice based on current guidelines.

Standard care

Brighton & Sussex University Hospitals NHS Trust

Kent, Surrey & Sussex CCGs

NHS Grampian

NHS Tayside

Bart's Health NHS Trust

Prescribing Asthma Controller Medication According to Gene Status to Improve Quality of Life in Young People With Asthma

A disease-specific health-related quality of life instrument that taps both physical and emotional impact of disease. Participants are asked to think about how they have been during the previous 2 weeks and to respond to each of the 32 questions on a 7-point scale (7 = not bothered at all - 1 = extremely bothered).

The ACQ has 6 questions (the top scoring 5 symptoms, and daily rescue bronchodilator use). Patients are asked to recall how their asthma has been during the previous week and to respond to the symptom and bronchodilator use questions on a 7-point scale (0=no impairment, 6= maximum impairment).

Participants will be asked to record how many times they have had to visit their GP or asthma nurse (outside of routine asthma review), A&E or hospital as a result of their asthma over the previous 3 months. Total scores for health care utilisation will be summed over the 12-month study period to create a total score for health care utilisation for each participant. Participants will be asked to enter this data via on the online questionnaire at each 3-month follow up.

Participants will be asked to record any courses of oral corticosteroids for asthma and any other medication use over the last 3 months. Medication use (scored by each type of medicinal product) will be summed across the 12 month study period to create total number of additional medicinal product use for each participant. Participants will be asked to enter this data via on the online questionnaire at each 3-month follow up.

University of Sussex

The participants will be randomised and at each study visit, will receive a single inhaler which can either be active or placebo.

Allergic Rhinitis

1. Fluticasone Propionate (FP) Product name: Flixotide Evohaler® Manufacturer: Allan and Hanbury's Active ingredients: Fluticasone Propionate Propellant: HFA 134a Dose: 250μg per actuation giving a total dose of 500µg per day through the spacer device with the customised nasal adaptor.

FLUTICASONE PROPRIONATE

Salmeterol Product Name: Serevent® Manufacturer: Allan and Hanbury's Active ingredients: Salmetrol Xinafoate Propellant: HFA 134a Dose: 25μg per actuation giving a total dose of 50µg per day through the spacer device with the customised nasal adaptor

Salmeterol

4. Placebo inhaler to SM, FP, SM+FP Manufacturer: Cipla Ltd Active ingredients: None Propellants: HFA 134a Imported & QP release tested in UK : DHP Clinical supplies, Powys, UK

PLACEBO

Asthma and Allergy Research Group, University of Dundee

Fluticasone and Salmeterol in Allergic Rhinitis

A Proof of Concept Study to Evaluate Effects of Intranasal Salmeterol and Fluticasone Given Alone and in Combination in Allergic Rhinitis

Maximum change in PNIF following nasal adenosine monophoshate (AMP) challenge testing for active groups versus placebo.. Data will be presented as % change between groups.

University of Dundee

Probiotic or placebo yogurt consumed daily

Mini Rhinoconjunctivitis Quality of Life Questionnaire

Blood sample

Nasal lavage

Lawson Health Research Institute - Canadian Research and Development Centre for Probiotics

The Anti-allergic Effects of Specific Probiotics

The Anti-allergic Effects of Specific Probiotics - a Double Blind Clinical Study

Gregor Reid

Principal Investigator

Lawson Health Research Institute

Ontario Ministry of Agriculture, Food and Rural Affairs

Addition of minocycline 150 mg po twice daily to current asthma treatment regimen.

Addition of placebo capsules po twice daily to current asthma treatment regimen

addition of antibiotic minocycline as antiinflammatory agent in addition to standard of care regimen.

minocycline

Addition of oral placebo capsule in addition to standard of care regimen

juniperus communis/protuupalno

Prescribing Asthma Controller Medication According to Gene Status to Improve Quality of Life in Young People With Asthma

Fluticasone and Salmeterol in Allergic Rhinitis

The Anti-allergic Effects of Specific Probiotics

Evaluation of the Utility of Minocycline as an Anti-Inflammatory Agent in the Treatment of Asthma

Najkompletnija baza ljekovitog bilja potpomognuta znanošću